Sign Out
Pregnancy: To date there is no available information on safety of use in pregnant women.
In animal studies, reproductive toxicity was observed. Consequently, oxaliplatin is not recommended during pregnancy and in women of childbearing potential not using contraceptive measures.
The use of oxaliplatin should only be considered after suitably appraising the patient of the risk to the foetus and with the patient's consent.
Appropriate contraceptive measures must be taken during and after cessation of therapy during 4 months for women.
Breast-feeding: Excretion in breast milk has not been studied. Breast-feeding is contraindicated during oxaliplatin therapy.
Fertility: Oxaliplatin may have an anti-fertility effect (see Precautions).
Due to the potential genotoxic effects of oxaliplatin, appropriate contraceptive measures must be taken during and after cessation of therapy during 4 months for women and 6 months for men.
